Citius Oncology, Net Working Capital Over Time
| CTOR Stock | 0.85 0.13 13.27% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Citius Oncology, Performance and Citius Oncology, Correlation. Citius |
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Citius Oncology,. If investors know Citius will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Citius Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Citius Oncology, is measured differently than its book value, which is the value of Citius that is recorded on the company's balance sheet. Investors also form their own opinion of Citius Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is Citius Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Citius Oncology,'s market value can be influenced by many factors that don't directly affect Citius Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Citius Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Citius Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Citius Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Working Capital Analysis
Compare Citius Oncology, and related stocks such as Getty Realty, Mangazeya Mining, and Waste Management Net Working Capital Over Time
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GTY | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 35.6 M | 66.6 M | 41.7 M | 79.1 M | 5.7 M | 66.2 M | 97.5 M | 61.7 M |
| WM | (638 M) | (638 M) | (638 M) | (638 M) | (638 M) | (638 M) | (638 M) | (638 M) | (463 M) | 3.1 B | (13 M) | (1 B) | (843 M) | (422 M) | (400.9 M) |
| ALVO | 35.2 M | 35.2 M | 35.2 M | 35.2 M | 35.2 M | 35.2 M | 35.2 M | 35.2 M | 35.2 M | 35.2 M | 35.2 M | 8 M | 63.4 M | (66.1 M) | (62.8 M) |
| WNW | (505.6 K) | (505.6 K) | (505.6 K) | (505.6 K) | (505.6 K) | (505.6 K) | (505.6 K) | (505.6 K) | (505.6 K) | (1.6 M) | 23.4 M | 24.2 M | 21.5 M | 12.8 M | 14.6 M |
| PFLT | (252.6 M) | (252.6 M) | (252.6 M) | (252.6 M) | (252.6 M) | (252.6 M) | (252.6 M) | (329.3 M) | (219.1 M) | (219.1 M) | (219.1 M) | (219.1 M) | (219.1 M) | (252 M) | (264.5 M) |
| KRG | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 33.6 M | 70.6 M | 64.3 M | 193.7 M | (282.6 M) | (87.9 M) | (83.5 M) |
Citius Oncology, and related stocks such as Getty Realty, Mangazeya Mining, and Waste Management Net Working Capital description
My Equities
My Current Equities and Potential Positions
| Citius Oncology, | CTOR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New Jersey; U.S.A |
| Exchange | NASDAQ Exchange |
null 0.85
Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.